Skip to main content
SpringerLink
Log in

Is ticagrelor safe in intensive care unit patients? Focus on bradycardic events

  • Letter
  • Published:
Intensive Care Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, PLATO Investigators, Freij A, Thorsén M (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045–1057

    Article  PubMed  CAS  Google Scholar 

  2. Scirica BM, Cannon CP, Emanuelsson H, Michelson EL, Harrington RA, Husted S, James S, Katus H, Pais P, Raev D, Spinar J, Steg PG, Storey RF, Wallentin L, PLATO Investigators (2011) The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (platelet inhibition and patient outcomes) trial. J Am Coll Cardiol 57:1908–1916

    Article  PubMed  CAS  Google Scholar 

  3. Cattaneo M, Schulz R, Nylander S (2014) Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol 63:2503–2509

    Article  PubMed  CAS  Google Scholar 

  4. Bonello L, Laine M, Kipson N, Mancini J, Helal O, Fromonot J, Gariboldi V, Condo J, Thuny F, Frere C, Camoin-Jau L, Paganelli F, Dignat-George F, Guieu R (2014) Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J Am Coll Cardiol 63:872–877

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Intensive Care, CHU de Caen, Caen, 14000, France

    Xavier Valette, Suzanne Goursaud, Maxime Leclerc & Damien du Cheyron

  2. Department of Pharmacology, CHU de Caen, Caen, 14000, France

    Joachim Alexandre

  3. Department of Cardiology, CHU de Caen, Caen, 14000, France

    Vincent Roule & Farzin Beygui

Authors
  1. Xavier Valette
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Suzanne Goursaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joachim Alexandre
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maxime Leclerc
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vincent Roule
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Farzin Beygui
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Damien du Cheyron
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xavier Valette.

Ethics declarations

Conflicts of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 16 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Valette, X., Goursaud, S., Alexandre, J. et al. Is ticagrelor safe in intensive care unit patients? Focus on bradycardic events. Intensive Care Med 44, 270–271 (2018). https://doi.org/10.1007/s00134-017-5006-7

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00134-017-5006-7

Search

Navigation